





Patent Docket P1994R1

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Clark et al.

Serial No.: 10/533,520

Filed: 28 April 2005

For: **COMPOSITIONS AND METHODS** 

FOR THE TREATMENT OF IMMUNE-

**RELATED DISEASES** 

Group Art Unit: Not Assigned

**Examiner: Not Assigned** 

Confirmation No: Not Assigned

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Bailev Le

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

#### 37 CFR §1.97(b) [x]

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

#### []37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of Serial No.: 10/533,520 Filing Date: 28 April 2005

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

## [] 37 CFR §1.97(d)

• after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449.

Copies of the items listed on the PTO-1449 form are supplied herewith, except for United States patent(s) and United States patent application publication(s) and other documents that are marked with an asterisk (\*) in the attached PTO-1449 form. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR § 1.98(a)(2)(ii)]. See Final Rule 1287 OG (October 12, 2004). Other documents cited with an asterisk have not been supplied because they were previously cited by or submitted to the Office in prior application Serial No. 60/429,069, filed 26 November 2002 and benefit from the prior application is claimed in this application under 35 U.S.C § 120. However, copies of any cited

Serial No.: 10/533,520 Filing Date: 28 April 2005

Page 3

document will be provided in its entirety at the request of the Office.

A concise explanation of relevance of the items listed on PTO-1449 is:

- [x] not given
- [] given for each listed item
- [] given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTERH/INC

Date: September (, 2005

David A. Carpenter

Reg. No. 45,945

Telephone No. (650)

FORM PTO-1449					U.S. Dept. of Commerce		Atty Docket No.		Serial No.		
				OIP &	ent and Trademark Office	e P199		10	/533,520		
			× 4 2 2 1 2 4 4 5		2	App	icant .				
LIST	OF DI	SCLOSURES CITED B	Y APPLICANT S	EP 0 8 200k	<b>&amp;</b> )		ry Sarah e				
(Use several sheets if necessary)					Filing Date		Group				
			(d)		28 Apr 2005			Not Assigned			
			`	MOEMAPORE	IGN PATENT DOCUME	INTS					
Examiner					_				Translation lass Yes No		
nitials		Document Number	Date	Country			Class		Subclass Yes		
	1	WO 01/75166 A2	11.10.01	PCT				<u> </u>			
				•	cluding Author, Title, Da		_	-			
	2	Chambers and Allison, "Co-Stimulation in T Cell Responses" Current Opinion in Immunology 9(3):396-404 (Jun 1997)									
	3	Coligan et al,, " Sons, Inc., Chapt			T Cell Function" C	urrent Pr	otocols in	Immunolo	ogy, John W	Viley &	
	4	Issekutz et al., and Very Late Act	"Treatment of ivation Antige	Established n-4 Integr	d Adjuvant Arthriti ins Suppresses Neut	s in Rats	with Mono	clonal Ar cyte Migr	tibody to ation to t	CD18 :he	
		Joints and Improv	ves Clinical Di The ups and dow	sease" Immu	nology 88:569-576 Il costimulation" <u>I</u>	(1996) mmunity 1	(6):443-44	6 (Sep 19	94)		
	. 5				otor Families" <u>Imm</u> u						
	6										
	7	Immunol. 11:191-2	212 (1993)		3 receptor during T						
	8	Nickoloff et al., of a new animal m	"Severe combinodel" Am. J. P	ned immunoo Path. 146(3)	deficiency mouse an :580-588 (Mar 1995	d human r	soriatic s	kin chime	eras. Valid	dation	
	9	Schon, M. P. et a 3(2):183-188 (Feb		oriasis-lil	ke disorder induced	by naive	CD4+ T ce	lls" <u>Nat</u>	Med.		
	10	Schwartz R., "Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy" Cell 71(7):1065-1068 (Dec 24, 1992)									
	-									·	
										_	
			_								
		,									
					· .						
Examine	r			,		Date Cor	sidered		···		
							p	-t			
*Examir if not	ier: In in con	itial it reterence consid formance and not cons	iered, whether or r sidered. Include co	not citation is opy of this for	in conformance with MF m with next communica	tion to appl	raw line throu icant.	gn citation			